{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:07:26Z","timestamp":1769202446887,"version":"3.49.0"},"reference-count":47,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.3892\/ijo.2015.2994","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T07:19:54Z","timestamp":1431328794000},"page":"253-261","source":"Crossref","is-referenced-by-count":7,"title":["CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation"],"prefix":"10.3892","volume":"47","author":[{"given":"ZHENGHUAN","family":"FANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KYUNG HEE","family":"JUNG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HONG HUA","family":"YAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SOO JUNG","family":"KIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MI KWON","family":"SON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARUFA","family":"RUMMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HYUNSEUNG","family":"LEE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KI WOON","family":"KIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HYE-DONG","family":"YOO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SOON-SUN","family":"HONG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,5,11]]},"reference":[{"key":"key20180107191059_b1-ijo-47-01-0253","first-page":"707","article-title":"Chronic myeloid leukemia: changing the treatment paradigms","volume":"20","author":"Savona","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"key20180107191059_b2-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"key20180107191059_b3-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"N Engl J Med"},{"key":"key20180107191059_b4-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2004-04-1242","article-title":"The Jab1\/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression","volume":"105","author":"Tomoda","year":"2005","journal-title":"Blood"},{"key":"key20180107191059_b5-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"key20180107191059_b6-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"key20180107191059_b7-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"key20180107191059_b8-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"key20180107191059_b9-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3892\/ol.2013.1225","article-title":"Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylate-resistant chronic myeloid leukemia patient","volume":"5","author":"Al-Achkar","year":"2013","journal-title":"Oncol Lett"},{"key":"key20180107191059_b10-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"key20180107191059_b11-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"key20180107191059_b12-ijo-47-01-0253","first-page":"121","article-title":"Nilotinib: A novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance","volume":"1","author":"Martinelli","year":"2007","journal-title":"Biologics"},{"key":"key20180107191059_b13-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"key20180107191059_b14-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/ars.2007.9.101","article-title":"The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms","volume":"9","author":"Goh","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"key20180107191059_b15-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/carcin\/bgm040","article-title":"The suppression of aberrant crypt multiplicity in colonic tissue of 1,2-dimethylhydrazine-treated C57BL\/6J mice by dietary flavone is associated with an increased expression of Krebs cycle enzymes","volume":"28","author":"Winkelmann","year":"2007","journal-title":"Carcinogenesis"},{"key":"key20180107191059_b16-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.dendro.2004.09.002","article-title":"Stand dynamics of a yellow-poplar (Liriodendron tulipifera L.) forest in the Appalachian Mountains, Virginia, USA","volume":"22","author":"Lafon","year":"2004","journal-title":"Dendrochronologia"},{"key":"key20180107191059_b17-ijo-47-01-0253","doi-asserted-by":"crossref","DOI":"10.5962\/bhl.title.524","volume-title":"Medical Flora or Manual of the Medical Botany of the United States of North America","author":"Rafinesque","year":"1828"},{"key":"key20180107191059_b18-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jep.2010.08.059","article-title":"Antiplasmodial activity of aporphine alkaloids and sesquiterpene lactones from Liriodendron tulipifera L","volume":"133","author":"Graziose","year":"2011","journal-title":"J Ethnopharmacol"},{"key":"key20180107191059_b19-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3390\/ijms14011698","article-title":"Biofunctional constituents from Liriodendron tulipifera with antioxidants and anti-melanogenic properties","volume":"14","author":"Li","year":"2013","journal-title":"Int J Mol Sci"},{"key":"key20180107191059_b20-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/jps.2600580720","article-title":"Antitumor agents. II Tulipinolide, a new germacranolide sesquiterpene, and constunolide Two cytotoxic substances from Liriodendron tulipifera L","volume":"58","author":"Doskotch","year":"1969","journal-title":"J Pharm Sci"},{"key":"key20180107191059_b21-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF02977609","article-title":"Farnesyl protein transferase and tumor cell growth inhibitory activities of lipiferolide isolated from Liriodendron tulipifera","volume":"30","author":"Moon","year":"2007","journal-title":"Arch Pharm Res"},{"key":"key20180107191059_b22-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1016\/j.bmcl.2009.05.092","article-title":"Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1)","volume":"19","author":"Neelakantan","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"key20180107191059_b23-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0962-8924(01)02173-0","article-title":"Programmed cell death: Alive and well in the new millennium","volume":"11","author":"Kaufmann","year":"2001","journal-title":"Trends Cell Biol"},{"key":"key20180107191059_b24-ijo-47-01-0253","first-page":"189","article-title":"Discovery of natural product anticancer agents from biodiverse organisms","volume":"12","author":"Kinghorn","year":"2009","journal-title":"Curr Opin Drug Discov Devel"},{"key":"key20180107191059_b25-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1021\/np050513p","article-title":"Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay","volume":"69","author":"Balunas","year":"2006","journal-title":"J Nat Prod"},{"key":"key20180107191059_b26-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/187220807779813893","article-title":"Nutraceuticals, nutritional therapy, phytonutrients, and phytotherapy for improvement of human health: A perspective on plant biotechnology application","volume":"1","author":"Zhao","year":"2007","journal-title":"Recent Pat Biotechnol"},{"key":"key20180107191059_b27-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1349-7006.2012.02409.x","article-title":"SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K\/Akt\/mTOR signaling pathway","volume":"103","author":"Hong","year":"2012","journal-title":"Cancer Sci"},{"key":"key20180107191059_b28-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"274786","DOI":"10.1155\/2014\/274786","article-title":"Effect of Uncaria tomentosa extract on apoptosis triggered by oxaliplatin exposure on HT29 cells","volume":"2014","author":"de Oliveira","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"key20180107191059_b29-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"key20180107191059_b30-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gde.2005.11.002","article-title":"Targeted CML therapy: Controlling drug resistance, seeking cure","volume":"16","author":"O\u2019Hare","year":"2006","journal-title":"Curr Opin Genet Dev"},{"key":"key20180107191059_b31-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CE.S6003","article-title":"Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review","volume":"4","author":"Jabbour","year":"2009","journal-title":"Core Evid"},{"key":"key20180107191059_b32-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","article-title":"Flying under the radar: The new wave of BCR-ABL inhibitors","volume":"6","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107191059_b33-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"key20180107191059_b34-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0301-472X(03)00069-9","article-title":"Mechanisms of Bcr-Abl-mediated NF-kappaB\/Rel activation","volume":"31","author":"Kirchner","year":"2003","journal-title":"Exp Hematol"},{"key":"key20180107191059_b35-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1093\/emboj\/cdf562","article-title":"The Src family kinase Hck couples BCR\/ABL to STAT5 activation in myeloid leukemia cells","volume":"21","author":"Klejman","year":"2002","journal-title":"EMBO J"},{"key":"key20180107191059_b36-ijo-47-01-0253","first-page":"1398","article-title":"Crkl enhances leukemogenesis in BCR\/ABL P190 transgenic mice","volume":"61","author":"Hemmeryckx","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107191059_b37-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"key":"key20180107191059_b38-ijo-47-01-0253","first-page":"880","article-title":"SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells","volume":"59","author":"Cabot","year":"1999","journal-title":"Cancer Res"},{"key":"key20180107191059_b39-ijo-47-01-0253","first-page":"1233","article-title":"Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in meta-static human colon cancer","volume":"61","author":"Selzner","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107191059_b40-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","article-title":"Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia","volume":"83","author":"Bedi","year":"1994","journal-title":"Blood"},{"key":"key20180107191059_b41-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1128\/MCB.24.23.10289-10299.2004","article-title":"Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release","volume":"24","author":"Deming","year":"2004","journal-title":"Mol Cell Biol"},{"key":"key20180107191059_b42-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cdd.4401210","article-title":"Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity","volume":"10","author":"Bueno-da-Silva","year":"2003","journal-title":"Cell Death Differ"},{"key":"key20180107191059_b43-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/BJ20100814","article-title":"Survivin and IAP proteins in cell-death mechanisms","volume":"430","author":"Altieri","year":"2010","journal-title":"Biochem J"},{"key":"key20180107191059_b44-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/CAD.0b013e328356cad9","article-title":"Sesquiterpene lactones as drugs with multiple targets in cancer treatment: Focus on parthenolide","volume":"23","author":"Kreuger","year":"2012","journal-title":"Anticancer Drugs"},{"key":"key20180107191059_b45-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1472-6882-12-89","article-title":"Sesquiterpene lactones isolated from indigenous Middle Eastern plants inhibit tumor promoter-induced transformation of JB6 cells","volume":"12","author":"Saikali","year":"2012","journal-title":"BMC Complement Altern Med"},{"key":"key20180107191059_b46-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/labinvest.2014.89","article-title":"Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer","volume":"94","author":"Viennois","year":"2014","journal-title":"Lab Invest"},{"key":"key20180107191059_b47-ijo-47-01-0253","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/carcin\/bgt255","article-title":"A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2\/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells","volume":"34","author":"Yeh","year":"2013","journal-title":"Carcinogenesis"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2015.2994\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T19:42:23Z","timestamp":1651952543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2015.2994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,11]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,5,11]]},"published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.3892\/ijo.2015.2994"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2015.2994","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,11]]}}}